Clinical Outcomes of Empagliflozin in the Treatment of Acute Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract
Objective: To evaluate the effectiveness of empagliflozin in patients with acute heart failure by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs).
Methodology: The recent systematic review and meta-analysis was conducted by following guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020. Four Electronic databases were used namely: PubMed, EMBASE, Clinicaltrials.gov and Cochrane library to find research articles. The Cochrane risk of bias tool was applied to assess the risk bias of included RCT’s and the pooled analysis was conducted by using RevMan (Review Manager) software version 5.4.
Results: About 13 RCT’s with 72,871 heart failure (HF) patients were analyzed to compare the effectiveness and safety of empagliflozin with placebo. The pooled analysis favored the experimental group as drug has controlled over first HF hospitalization among heart failure patients (Odds Ratio= 0.67; 0.52 to 0.876 Cl: 95%, p=0.13), total HF hospitalization among heart failure patients as (Odds Ratio=0.55; 0.42 to 0.74 Cl: 95%, p<0.00001), and total adverse events (fatal or non-fatal outcomes) among heart failure patients as (Odds Ratio=0.59; 0.40 to 0.88 Cl: 95%, p<0.00001). However, the levels of LVEF and NT-proBNP were reduced as reported through mean difference of LVEF (Mean difference= 0.41; -0.81 to 1.64 Cl: 95%, p<0.00001) and NT- proBNP among empagliflozin and placebo groups (Mean difference= -1.55; -7.00…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.